Kintara Therapeutics Inc
NASDAQ:KTRA

Watchlist Manager
Kintara Therapeutics Inc Logo
Kintara Therapeutics Inc
NASDAQ:KTRA
Watchlist
Price: 6.3 USD -16.43% Market Closed
Market Cap: 266.4m USD
Have any thoughts about
Kintara Therapeutics Inc?
Write Note
KTRA
/
Cash Flow Statement
/
Net Issuance of Debt

Kintara Therapeutics Inc
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kintara Therapeutics Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Kintara Therapeutics Inc
NASDAQ:KTRA
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Debt
$9.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Debt
-$360m
CAGR 3-Years
N/A
CAGR 5-Years
41%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Debt
-$42.5m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kintara Therapeutics Inc
Glance View

Market Cap
266.4m USD
Industry
Biotechnology

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.

KTRA Intrinsic Value
6.92 USD
Undervaluation 9%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.